Short-term outcomes and intermediate-term follow-up ofHelicobacter pyloriinfection treatment for naïve patients: a retrospective observational study

Abstract

ObjectivesTo explore the outcomes ofHelicobacter pyloriinfection treatments for naïve patients in the real-world settings.DesignA retrospective observational study.SettingSingle tertiary level academic hospital in China.ParticipantsWe identified patients initially receiving quadruple therapy forH. pyloriinfection from 2017 to 2020 in whom eradication was confirmed (n=23 470).Primary outcomeEfficacy of different initialH. pyloriinfection treatments.Secondary outcomeResults of urea breath test (UBT) afterH. pylorieradication.ResultsAmong 23 470 patients who received initialH. pyloritreatment, 21 285 (90.7%) were treated with amoxicillin-based regimens. The median age of the patients decreased from 2017 to 2020 (45.0 vs 39.0, p<0.0001). The main treatments were therapies containing amoxicillin and furazolidone, which had an eradication rate of 87.6% (14 707/16 784); those containing amoxicillin and clarithromycin had an eradication rate of 85.5% (3577/4182). The date of treatment, age, antibiotic regimen and duration of treatment showed correlations with the failure ofH. pylorieradication in a multivariable logistic regression analysis. Finally, positive UBT results after eradication clustered around the cut-off value, in both the13C-UBT and14C-UBT.ConclusionsThe majorH. pyloriinfection treatments for naïve patients were those containing amoxicillin and furazolidone, which offered the highest eradication rate. The date of treatment, age, antibiotic regimen and duration of treatment were risk factors for the failure ofH. pylorieradication. Additionally, positive UBT results after eradication clustered around the cut-off value.